These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

300 related items for PubMed ID: 17606726

  • 1. Mechanism of action and preclinical antitumor activity of the novel hypoxia-activated DNA cross-linking agent PR-104.
    Patterson AV, Ferry DM, Edmunds SJ, Gu Y, Singleton RS, Patel K, Pullen SM, Hicks KO, Syddall SP, Atwell GJ, Yang S, Denny WA, Wilson WR.
    Clin Cancer Res; 2007 Jul 01; 13(13):3922-32. PubMed ID: 17606726
    [Abstract] [Full Text] [Related]

  • 2. DNA cross-links in human tumor cells exposed to the prodrug PR-104A: relationships to hypoxia, bioreductive metabolism, and cytotoxicity.
    Singleton RS, Guise CP, Ferry DM, Pullen SM, Dorie MJ, Brown JM, Patterson AV, Wilson WR.
    Cancer Res; 2009 May 01; 69(9):3884-91. PubMed ID: 19366798
    [Abstract] [Full Text] [Related]

  • 3. Oxygen dependence and extravascular transport of hypoxia-activated prodrugs: comparison of the dinitrobenzamide mustard PR-104A and tirapazamine.
    Hicks KO, Myint H, Patterson AV, Pruijn FB, Siim BG, Patel K, Wilson WR.
    Int J Radiat Oncol Biol Phys; 2007 Oct 01; 69(2):560-71. PubMed ID: 17869669
    [Abstract] [Full Text] [Related]

  • 4. Roles of DNA repair and reductase activity in the cytotoxicity of the hypoxia-activated dinitrobenzamide mustard PR-104A.
    Gu Y, Patterson AV, Atwell GJ, Chernikova SB, Brown JM, Thompson LH, Wilson WR.
    Mol Cancer Ther; 2009 Jun 01; 8(6):1714-23. PubMed ID: 19509245
    [Abstract] [Full Text] [Related]

  • 5. Pre-clinical activity of PR-104 as monotherapy and in combination with sorafenib in hepatocellular carcinoma.
    Abbattista MR, Jamieson SM, Gu Y, Nickel JE, Pullen SM, Patterson AV, Wilson WR, Guise CP.
    Cancer Biol Ther; 2015 Jun 01; 16(4):610-22. PubMed ID: 25869917
    [Abstract] [Full Text] [Related]

  • 6. Identification of human reductases that activate the dinitrobenzamide mustard prodrug PR-104A: a role for NADPH:cytochrome P450 oxidoreductase under hypoxia.
    Guise CP, Wang AT, Theil A, Bridewell DJ, Wilson WR, Patterson AV.
    Biochem Pharmacol; 2007 Sep 15; 74(6):810-20. PubMed ID: 17645874
    [Abstract] [Full Text] [Related]

  • 7. Reductive metabolism of the dinitrobenzamide mustard anticancer prodrug PR-104 in mice.
    Gu Y, Guise CP, Patel K, Abbattista MR, Li J, Sun X, Atwell GJ, Boyd M, Patterson AV, Wilson WR.
    Cancer Chemother Pharmacol; 2011 Mar 15; 67(3):543-55. PubMed ID: 20473609
    [Abstract] [Full Text] [Related]

  • 8. Drug-DNA adducts as biomarkers for metabolic activation of the nitro-aromatic nitrogen mustard prodrug PR-104A.
    Stornetta A, Deng KK, Danielli S, Liyanage HDS, Sturla SJ, Wilson WR, Gu Y.
    Biochem Pharmacol; 2018 Aug 15; 154():64-74. PubMed ID: 29630868
    [Abstract] [Full Text] [Related]

  • 9. The bioreductive prodrug PR-104A is activated under aerobic conditions by human aldo-keto reductase 1C3.
    Guise CP, Abbattista MR, Singleton RS, Holford SD, Connolly J, Dachs GU, Fox SB, Pollock R, Harvey J, Guilford P, Doñate F, Wilson WR, Patterson AV.
    Cancer Res; 2010 Feb 15; 70(4):1573-84. PubMed ID: 20145130
    [Abstract] [Full Text] [Related]

  • 10. SJG-136 (NSC 694501), a novel rationally designed DNA minor groove interstrand cross-linking agent with potent and broad spectrum antitumor activity: part 1: cellular pharmacology, in vitro and initial in vivo antitumor activity.
    Hartley JA, Spanswick VJ, Brooks N, Clingen PH, McHugh PJ, Hochhauser D, Pedley RB, Kelland LR, Alley MC, Schultz R, Hollingshead MG, Schweikart KM, Tomaszewski JE, Sausville EA, Gregson SJ, Howard PW, Thurston DE.
    Cancer Res; 2004 Sep 15; 64(18):6693-9. PubMed ID: 15374986
    [Abstract] [Full Text] [Related]

  • 11. Initial testing of the hypoxia-activated prodrug PR-104 by the pediatric preclinical testing program.
    Houghton PJ, Lock R, Carol H, Morton CL, Phelps D, Gorlick R, Kolb EA, Keir ST, Reynolds CP, Kang MH, Maris JM, Wozniak AW, Gu Y, Wilson WR, Smith MA.
    Pediatr Blood Cancer; 2011 Sep 15; 57(3):443-53. PubMed ID: 21744473
    [Abstract] [Full Text] [Related]

  • 12. A phase I trial of PR-104, a nitrogen mustard prodrug activated by both hypoxia and aldo-keto reductase 1C3, in patients with solid tumors.
    Jameson MB, Rischin D, Pegram M, Gutheil J, Patterson AV, Denny WA, Wilson WR.
    Cancer Chemother Pharmacol; 2010 Mar 15; 65(4):791-801. PubMed ID: 20012293
    [Abstract] [Full Text] [Related]

  • 13. Analysis of the hypoxia-activated dinitrobenzamide mustard phosphate pre-prodrug PR-104 and its alcohol metabolite PR-104A in plasma and tissues by liquid chromatography-mass spectrometry.
    Patel K, Lewiston D, Gu Y, Hicks KO, Wilson WR.
    J Chromatogr B Analyt Technol Biomed Life Sci; 2007 Sep 01; 856(1-2):302-11. PubMed ID: 17644498
    [Abstract] [Full Text] [Related]

  • 14. Hypoxia-selective antitumor agents. 16. Nitroarylmethyl quaternary salts as bioreductive prodrugs of the alkylating agent mechlorethamine.
    Tercel M, Lee AE, Hogg A, Anderson RF, Lee HH, Siim BG, Denny WA, Wilson WR.
    J Med Chem; 2001 Oct 11; 44(21):3511-22. PubMed ID: 11585455
    [Abstract] [Full Text] [Related]

  • 15. Glucuronidation of anticancer prodrug PR-104A: species differences, identification of human UDP-glucuronosyltransferases, and implications for therapy.
    Gu Y, Tingle MD, Wilson WR.
    J Pharmacol Exp Ther; 2011 Jun 11; 337(3):692-702. PubMed ID: 21427202
    [Abstract] [Full Text] [Related]

  • 16. A novel fluorometric assay for aldo-keto reductase 1C3 predicts metabolic activation of the nitrogen mustard prodrug PR-104A in human leukaemia cells.
    Jamieson SM, Gu Y, Manesh DM, El-Hoss J, Jing D, Mackenzie KL, Guise CP, Foehrenbacher A, Pullen SM, Benito J, Smaill JB, Patterson AV, Mulaw MA, Konopleva M, Bohlander SK, Lock RB, Wilson WR.
    Biochem Pharmacol; 2014 Mar 01; 88(1):36-45. PubMed ID: 24434189
    [Abstract] [Full Text] [Related]

  • 17. Bystander effects of bioreductive drugs: potential for exploiting pathological tumor hypoxia with dinitrobenzamide mustards.
    Wilson WR, Hicks KO, Pullen SM, Ferry DM, Helsby NA, Patterson AV.
    Radiat Res; 2007 Jun 01; 167(6):625-36. PubMed ID: 17523848
    [Abstract] [Full Text] [Related]

  • 18. Synthesis and structure-activity relationships for 2,4-dinitrobenzamide-5-mustards as prodrugs for the Escherichia coli nfsB nitroreductase in gene therapy.
    Atwell GJ, Yang S, Pruijn FB, Pullen SM, Hogg A, Patterson AV, Wilson WR, Denny WA.
    J Med Chem; 2007 Mar 22; 50(6):1197-212. PubMed ID: 17326614
    [Abstract] [Full Text] [Related]

  • 19. The Role of Bystander Effects in the Antitumor Activity of the Hypoxia-Activated Prodrug PR-104.
    Foehrenbacher A, Patel K, Abbattista MR, Guise CP, Secomb TW, Wilson WR, Hicks KO.
    Front Oncol; 2013 Mar 22; 3():263. PubMed ID: 24109591
    [Abstract] [Full Text] [Related]

  • 20. A combined pharmacokinetic model for the hypoxia-targeted prodrug PR-104A in humans, dogs, rats and mice predicts species differences in clearance and toxicity.
    Patel K, Choy SS, Hicks KO, Melink TJ, Holford NH, Wilson WR.
    Cancer Chemother Pharmacol; 2011 May 22; 67(5):1145-55. PubMed ID: 20683596
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.